ORIC outlines 2023 milestones: initial Phase 1b data expected H2 2023 for three programs

Oric Pharmaceuticals, Inc.

Initial Phase 1b data expected H2 2023 for ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2 cancers), ORIC-944 (prostate cancer).
Pfizer invested $25M in ORIC common stock as part of ORIC-533 clinical collaboration.
Cash and investments $228M as of Dec 31, 2022; runway into H1 2025.
Selected PLK4 inhibitor as development candidate for breast cancer (TRIM37-amplified) in Q4 2022.
All three clinical programs dose-escalating steadily without reaching MTD; global site expansion ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.